SGLT2 inhibitors for heart and kidney

Was ist neu? Funktion von SGLT2-Inhibitoren und pathophysiologische Effekte Natrium-Glukose-Co-Transporter-2-Inhibitoren (SGLT2) konnen die Glukose-Reabsorption im proximalen Tubulus blockieren und spielen damit eine wichtige Rolle in der Zuckerkontrolle beim Diabetes mellitus. Erweiterung des Einsatzgebietes von SGLT2 Zusatzlich zur glukosurischen Wirkung wurden eher uberraschend sehr umfangreiche, weitere positive Effekte bei chronischen Nierenfunktionsstorungen beobachtet. Auch zeigte sich eine starke kardioprotektive Wirkung bei der Herzinsuffizienz. Mittlerweile wurden zahlreiche Mechanismen abseits der reinen zuckerbeeinflussenden Wirkung der SGLT2-Inhibitioren identifiziert, die sowohl das Herz als auch die Niere direkt positiv beeinflussen konnen. Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors can block glucose reabsorption in the proximal tubule and thus play an important role in glycemic control in diabetes mellitus. In addition to glucosuric effects, surprisingly very extensive other positive effects were observed in chronic renal dysfunction and strong cardioprotective effects in heart failure. In the meantime, numerous mechanisms have been identified apart from the pure sugar-influencing effect of the SGLT2 inhibitors, which can have a direct positive influence heart and kidneys. In recent years there has been an extensive clinical study program, which has dealt with the effects of SGLT2 inhibitors on the progression of diabetic and non-diabetic chronic renal failure. It could be shown that patients with albuminuria have a significant benefit from the use of SGLT2 inhibitors. Therefore, the progression of renal dysfunction is slowed down significantly, while at the same time, positive cardiovascular endpoints could be influenced. Numerous studies have also been conducted in patients with and without diabetes or with heart failure, with and without, preserved ejection fraction. Impressive protection was also shown here, with the benefit of using SGLT2 inhibitors to reduce heart failure worsening. In a short period of 10 years, the use of SGLT2 inhibitors was established as an essential therapy for cardio-renal indications to inhibit the progression of renal failure as well as to protect against heart failure apart from pure diabetes therapy. In numerous guidelines (ESC heart failure, KDGIO diabetes, ESH hypertension), the early use of SGLT2 inhibitors is now recommended for protection against cardio-renal events and is an important first-line addition to the previously established therapies. Apart from diabetes therapy, it offers patients completely new options in cardio-renal protection.